Esperion Therapeutics (ESPR) Other Accumulated Expenses (2012 - 2023)

Esperion Therapeutics has reported Other Accumulated Expenses for 12 years, with the latest figure at $25.0 million in Q4 2023.

• For the quarter ending Q4 2023, Other Accumulated Expenses rose 89.32% year-over-year to $25.0 million; the trailing twelve-month figure through Dec 2023 stood at $25.0 million (up 89.32% YoY), and the FY2023 full-year result was $25.0 million, up 89.32% from the prior year.
• Other Accumulated Expenses for Q4 2023 stood at $25.0 million, up from $13.2 million in the prior quarter.
• The five-year high for Other Accumulated Expenses was $30.4 million in Q4 2021, with the low at $3.2 million in Q1 2020.
• Historically, Other Accumulated Expenses has averaged $13.0 million across 5 years, with a median of $10.9 million in 2019.
• Annual changes were most pronounced in 2019 — Other Accumulated Expenses surged 249.04% — and 2022, when it tumbled 56.58%.
• Esperion Therapeutics' Other Accumulated Expenses stood at $11.9 million in 2019, then soared by 108.83% to $24.8 million in 2020, then gained by 22.67% to $30.4 million in 2021, then plunged by 56.58% to $13.2 million in 2022, then jumped by 89.32% to $25.0 million in 2023.
• The last three Other Accumulated Expenses figures came in at $25.0 million (Q4 2023), $13.2 million (Q4 2022), and $30.4 million (Q4 2021), per Business Quant data.